U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07729670) titled 'Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC' on June 14.
Brief Summary: This is a prospective, open-label, single-center, single-arm phase II clinical trial evaluating the efficacy and safety of multimodal ablation in combination with perioperative tislelizumab and chemotherapy in patients with pathologically confirmed resectable stage II-IIIB (N2) non-small cell lung cancer (NSCLC).
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
NSCLC
Intervention:
DEVICE: Multimodal Ablation
CT-guided preoperative multimodal ablation performed with multimodal...